An interventional study of Deprox_HP and Peacist in Male Infertility and Prostatitis, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to male participants aged 20 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Treatment
Male Accessory Glands Inflammations (MAGI) include inflammatory diseases involving seminal vescicles and the prostate. Patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. Inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as SuPAR and ST2. Treatment of MAGIs include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. Deprox HP is a nutraceutic containing GraminexTM, a compound made of pollen extracts of rye, mais and timothy. To investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking Deprox HP and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.
282 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 187 interventional studies indexed under Infertility, Male.
Browse Infertility, Male studies →Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with MAGI that will be given Deprox HP therapy
Other: Deprox_HP
Patients with MAGI that will be given PEA+bromelin+horse chestnut extract
Other: Peacist
Use of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy
Use of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract
Modifications of number of spermatozoa
Modifications of the number of spermatozoa in Millions
Time frame: 6 months
Modification of sperm motility
Modification of sperm progressive motility in %
Time frame: 6 months
Modifications of number of typical forms
Modifications of number of typical forms in %
Time frame: 6 months
Modifications of seminal inflammatory parameters
Modifications of seminal inflammatory parameters ST2 and SuPAR, both expressed in ng/mL
Time frame: 6 months
Modifications of seminal oxidative parameters
Modifications of reactive oxygen species expressed in mEq
Time frame: 6 months
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →